A. Westermann

发表

A nationwide analysis of incidence and outcome of breast cancer in the country of Surinam, during 1994–2003

F. Rijmen, O. Visser, R. S. Leeuwaarde, 2011, Breast Cancer Research and Treatment.

Increased dihydropyrimidine dehydrogenase activity associated with mild toxicity in patients treated with 5-fluorouracil and leucovorin.

Henk-Jan Guchelaar, A. V. van Kuilenburg, D. Richel, 2007, European journal of cancer.

Long-term survival data of triple modality treatment of stage IIB–III–IVA cervical cancer with the combination of radiotherapy, chemotherapy and hyperthermia – an update

J. van der Zee, P. Koper, L. Prosnitz, 2012, International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group.

Prognostic Value of Residual Disease after Interval Debulking Surgery for FIGO Stage IIIC and IV Epithelial Ovarian Cancer

G. Kenter, G. Sonke, M. Buist, 2015, Obstetrics and gynecology international.

The impact of the oral cavity in febrile neutropenia and infectious complications in patients treated with myelosuppressive chemotherapy

L. Smeele, J. Epstein, J. Raber-Durlacher, 2019, Supportive Care in Cancer.

Weekly docetaxel in metastatic breast cancer patients: no superior benefits compared to three-weekly docetaxel.

W. M. Smit, P. Willemse, A. Westermann, 2011, European journal of cancer.

Phase II randomized study of trabectedin given as two different every 3 weeks dose schedules (1.5 mg/m2 24 h or 1.3 mg/m2 3 h) to patients with relapsed, platinum-sensitive, advanced ovarian cancer.

T. Ciuleanu, M. Wojtukiewicz, C. Lebedinsky, 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

Gynecologic Cancer InterGroup (GCIG) Consensus Review: Uterine and Ovarian Leiomyosarcomas

Jae-Weon Kim, I. Ray-Coquard, D. Gaffney, 2014, International Journal of Gynecologic Cancer.

Diagnostic dilemma in a man with seminoma

A. Westermann, H. Klümpen, 2004, The Lancet.

Novel applications of growth factors in solid tumors

S. Rodenhuis, J. Beijnen, W. Moolenaar, 1999 .

Malignant effusions contain lysophosphatidic acid (LPA)-like activity.

S. Rodenhuis, O. Dalesio, J. Beijnen, 1998, Annals of oncology : official journal of the European Society for Medical Oncology.

An impressive response to pazopanib in a patient with metastatic endometrial carcinoma.

B. Tops, P. Ottevanger, A. Westermann, 2016, The Netherlands journal of medicine.

The Potential Contribution of Dental Foci and Oral Mucositis to Febrile Neutropenia in Patients Treated With Myelosuppressive Chemotherapy for Solid Tumors and Lymphoma

L. Smeele, J. Raber-Durlacher, A. Westermann, 2022, Frontiers in Oral Health.

RANKL inhibition for giant cell lesions of the jaw: A retrospective cohort analysis.

M. Witjes, H. Gelderblom, A. Westermann, 2022, European journal of cancer.

Feasibility of multiple courses of high-dose cyclophosphamide, thiotepa, and carboplatin for breast cancer or germ cell cancer.

S. Rodenhuis, J. Baars, J. Schornagel, 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Comparing cisplatin-based combination chemotherapy with EMA/CO chemotherapy for the treatment of high risk gestational trophoblastic neoplasia.

F. Sweep, R. Verheijen, L. Massuger, 2013, European journal of cancer.

Feasibility and pharmacokinetics of intraperitoneal suramin in advanced malignancy

S. Rodenhuis, J. Beijnen, W. Moolenaar, 2000, Cancer Chemotherapy and Pharmacology.

This is a repository copy of A randomized double-blind phase II study evaluating the role of maintenance therapy with cabozantinib in high-grade uterine sarcoma after stabilization or response to doxorubicin ± ifosfamide following surgery or in metastatic first line

Robin L. Jones, I. Ray-Coquard, B. Seddon, 2020 .

At home management of aplastic phase following high-dose chemotherapy with stem-cell rescue for hematological and non-hematological malignancies.

S. Rodenhuis, J. Schornagel, A. Westermann, 1999, Annals of oncology : official journal of the European Society for Medical Oncology.

Sensitizing thermochemotherapy with a PARP1-inhibitor

L. Stalpers, R. Kanaar, J. Crezee, 2016, Oncotarget.

Fifth Ovarian Cancer Consensus Conference of the Gynecologic Cancer InterGroup (GCIG): clinical trial design for rare ovarian tumours.

E. Kohn, A. Okamoto, D. Provencher, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

Sequence-dependent toxicity profile in modified FAMTX (fluorouracil-adriamycin-methotrexate) chemotherapy with lenograstim support for advanced gastric cancer: a feasibility study.

H. Boot, B. Taal, W. Gerritsen, 2000, Pharmacological research.

Gynecologic Cancer InterGroup (GCIG) Consensus Review for High-Grade Undifferentiated Sarcomas of the Uterus

D. Provencher, I. Ray-Coquard, P. Harter, 2014, International Journal of Gynecologic Cancer.

Primary intracranial germ-cell tumors in adults: a practical review

P. Wesseling, B. Baumert, A. Westermann, 2013, Journal of Neuro-Oncology.

Some unusual paraneoplastic syndromes. Case 2. Digital ulceration as a paraneoplastic syndrome in ovarian cancer.

A. Westermann, P. D. de Jong, J. P. Baars, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Full-dose cisplatin chemotherapy combined with hemodialysis in a patient with impaired renal function and a mediastinal germ cell tumor

J. Bijlsma, A. Westermann, N. Jager, 2020, Anti-cancer drugs.

Growth factors in human ovarian cancer.

S. Rodenhuis, J. Beijnen, W. Moolenaar, 1997, Cancer treatment reviews.

Successful intraperitoneal suramin treatment of peritoneal mesothelioma.

S. Rodenhuis, J. Beijnen, W. Moolenaar, 1997, Annals of oncology : official journal of the European Society for Medical Oncology.

Plasma lysophosphatidic acid concentration and ovarian cancer.

Daniel L Baker, Gabor Tigyi, D. Baker, 2002, JAMA.

ESGO/ESTRO/ESP Guidelines for the management of patients with endometrial carcinoma

S. Marnitz, J. Ledermann, I. Vergote, 2021, Virchows Archiv.

ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma.

Cyrus Chargari, S. Marnitz, J. Ledermann, 2021, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma

Cyrus Chargari, S. Marnitz, J. Ledermann, 2020, International Journal of Gynecological Cancer.

Two Cases of Hepatoblastoma in Young Adults.

T. V. van Gulik, A. Westermann, J. Verheij, 2018, Journal of adolescent and young adult oncology.

MILO/ENGOT-ov11: Binimetinib Versus Physician’s Choice Chemotherapy in Recurrent or Persistent Low-Grade Serous Carcinomas of the Ovary, Fallopian Tube, or Primary Peritoneum

B. Monk, A. Oza, I. Vergote, 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

mTOR inhibitor treatment of pancreatic cancer in a patient With Peutz-Jeghers syndrome.

D. Richel, C. Spek, C. V. van Noesel, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Spinal cord compression due to Kaposi's sarcoma.

Z. Wszolek, A. Westermann, S. van Eeden, 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

Results of concurrent chemotherapy and hyperthermia in patients with recurrent cervical cancer after previous chemoradiation

L. Stalpers, H. V. van Doorn, A. Westermann, 2014, International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group.

ZoptEC: Phase III randomized controlled study comparing zoptarelin with doxorubicin as second line therapy for locally advanced, recurrent, or metastatic endometrial cancer (NCT01767155).

A. Oza, R. Wenham, H. Gabra, 2018 .

Trial in progress update on ENGOT-cx8/GOG-3024/innovaTV 205: Addition of a new cohort with first-line (1L) tisotumab vedotin (TV) + pembrolizumab (pembro) + carboplatin (carbo) ± bevacizumab (bev) in recurrent/metastatic cervical cancer (r/mCC).

B. Monk, I. Vergote, J. Sehouli, 2022, Journal of Clinical Oncology.

Enhancing synthetic lethality of PARP-inhibitor and cisplatin in BRCA-proficient tumour cells with hyperthermia

L. Stalpers, R. Kanaar, J. Crezee, 2017, Oncotarget.

Gynecologic Cancer InterGroup (GCIG) Consensus Review for Endometrial Stromal Sarcoma

M. Friedlander, I. Ray-Coquard, B. Seddon, 2014, International Journal of Gynecologic Cancer.

The European Network for Gynaecological Oncological Trial Groups Charta for Privileged Partnership

J. Ledermann, R. Glasspool, I. Vergote, 2015, International Journal of Gynecologic Cancer.

Efficacy and safety of durvalumab with olaparib in metastatic or recurrent endometrial cancer (phase II DOMEC trial).

H. Putter, T. Bosse, A. Westermann, 2022, Gynecologic oncology.

Tisotumab vedotin (TV) + pembrolizumab (pembro) in first-line (1L) recurrent or metastatic cervical cancer (r/mCC): Interim results of ENGOT Cx8/GOG 3024/innovaTV 205.

B. Monk, I. Vergote, S. Pignata, 2022, Journal of Clinical Oncology.

723MO Tisotumab vedotin (TV) + carboplatin (Carbo) in first-line (1L) or + pembrolizumab (Pembro) in previously treated (2L/3L) recurrent or metastatic cervical cancer (r/mCC): Interim results of ENGOT-Cx8/GOG-3024/innovaTV 205 study

S. Pignata, M. Mirza, S. Banerjee, 2021, Annals of Oncology.

PARP and PD-1/PD-L1 checkpoint inhibition in recurrent or metastatic endometrial cancer.

T. Bosse, A. Westermann, J. Kroep, 2020, Critical reviews in oncology/hematology.

Catumaxomab with and without prednisolone premedication for the treatment of malignant ascites due to epithelial cancer: results of the randomised phase IIIb CASIMAS study

C. Tournigand, A. Schneeweiss, C. Bokemeyer, 2014, Medical Oncology.

Molecular results and potential biomarkers identified from MILO/ENGOT-ov11 phase 3 study of binimetinib versus physicians choice of chemotherapy (PCC) in recurrent low-grade serous ovarian cancer (LGSOC).

B. Monk, A. Oza, I. Vergote, 2021 .

An assisted structured reflection on life events and life goals in advanced cancer patients: Outcomes of a randomized controlled trial (Life InSight Application (LISA) study)

M. Sprangers, M. V. van Oijen, W. Meijer, 2018, Palliative medicine.

Phase I trial to determine the safety and tolerability of GW572016 in combination with oxaliplatin (OX)/5-fluorouracil (5-FU)/leucovorin (LV) [FOLFOX4] in patients with solid tumors.

D. Richel, J. Schellens, J. Beijnen, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A Systemic Hyperthermia Oncologic Working Group Trial

D. Jäger, J. Dijk, D. Katschinski, 2003, Oncology.

Pharmacological and surgical therapy for the central giant cell granuloma: A long-term retrospective cohort study.

A. Westermann, Z. Peacock, H. van den Berg, 2017, Journal of cranio-maxillo-facial surgery : official publication of the European Association for Cranio-Maxillo-Facial Surgery.

A pilot study of whole body hyperthermia and carboplatin in platinum-resistant ovarian cancer.

D. Jäger, R. Rietbroek, D. Katschinski, 2001, European Journal of Cancer.

Successful docetaxel rechallenge with cromoglycate after major sensitivity reactions.

S. Rodenhuis, W. W. ten Bokkel Huinink, A. Westermann, 1996, Annals of oncology : official journal of the European Society for Medical Oncology.

[Severe toxicity after treatment with capecitabine and fluorouracil due to partial dihydropyrimidine dehydrogenase deficiency].

A. V. van Kuilenburg, J. Haanen, A. Westermann, 2004, Nederlands tijdschrift voor geneeskunde.

A short time interval between radiotherapy and hyperthermia reduces in-field recurrence and mortality in women with advanced cervical cancer

H. P. Kok, L. Stalpers, A. Bel, 2017, Radiation Oncology.

Effectiveness of Chemotherapy in Measurable Granulosa Cell Tumors: A Retrospective Study and Review of Literature

G. Kenter, G. Sonke, M. Buist, 2014, International Journal of Gynecologic Cancer.

Phase I study of cisplatin, hyperthermia, and lapatinib in patients with recurrent carcinoma of the uterine cervix in a previously irradiated area.

S. Sleijfer, E. Wiemer, A. Westermann, 2015, The oncologist.

First results of triple‐modality treatment combining radiotherapy, chemotherapy, and hyperthermia for the treatment of patients with Stage IIB, III, and IVA cervical carcinoma

J. van der Zee, P. Koper, L. Prosnitz, 2005, Cancer.

Outcome of Nonsurgical Management of Extra-Abdominal, Trunk, and Abdominal Wall Desmoid-Type Fibromatosis: A Population-Based Study in the Netherlands

F. van Coevorden, M. D. den Bakker, H. Gelderblom, 2018, Sarcoma.

Post-operative radiotherapy in patients with early stage cervical cancer.

G. Kenter, L. Stalpers, C. Rasch, 2014, Gynecologic oncology.

Quantification of the contribution of hyperthermia to results of cervical cancer trials: in regard to Plataniotis and Dale (Int J Radiat Oncol Biol Phys 2009;73:1538-1544).

E. D. Geijsen, J. Haveman, L. Stalpers, 2009, International journal of radiation oncology, biology, physics.

A short time interval between radiotherapy and hyperthermia reduces in-field recurrence and mortality in women with advanced cervical cancer

H. P. Kok, L. Stalpers, A. Bel, 2017, Radiation oncology.

A randomized phase-II study of reirradiation and hyperthermia versus reirradiation and hyperthermia plus chemotherapy for locally recurrent breast cancer in previously irradiated area

R. V. van Os, H. Crezee, A. Westermann, 2022, Acta oncologica.

High-dose chemotherapy in breast cancer. The Dutch trial

S. Rodenhuis, O. Dalesio, M. Nooij, 2001 .

Pre-Chemotherapy Dental Screening: Is There Additional Diagnostic Value for a Panoramic Radiograph?

J. Raber-Durlacher, A. Westermann, L. Smeele, 2023, Dentistry journal.

UvA-DARE ( Digital Academic Repository ) Tumor cells can ’ t stand the heat Boosting the effectiveness of hyperthermia in cervical carcinoma

L. Stalpers, A. Westermann, H. Rodermond, 2017 .

INOVATYON/ ENGOT-ov5 study: Randomized phase III international study comparing trabectedin/pegylated liposomal doxorubicin (PLD) followed by platinum at progression vs carboplatin/PLD in patients with recurrent ovarian cancer progressing within 6-12 months after last platinum line

D. Katsaros, L. Cavanna, I. Meinhold-Heerlein, 2023, British Journal of Cancer.

Phase II open label randomized study of trabectedin (T) given as two different dosing schedules in women with platinum-sensitive, recurrent ovarian carcinoma: Preliminary results.

T. Ciuleanu, A. Poveda, M. Izquierdo, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II study of carboplatin and whole body hyperthermia (WBH) in recurrent and metastatic cervical cancer.

R. Rietbroek, J. Dijk, A. Westermann, 2004, Gynecologic oncology.

Altered Dihydropyrimidine Dehydrogenase Activity Associated with Mild Toxicity in Patients Treated with 5-Fluorouracil Containing Chemotherapy

A. V. van Kuilenburg, D. Richel, L. Zoetekouw, 2008, Nucleosides, nucleotides & nucleic acids.

Molecular Results and Potential Biomarkers Identified from the Phase 3 MILO/ENGOT-ov11 Study of Binimetinib versus Physician Choice of Chemotherapy in Recurrent Low-Grade Serous Ovarian Cancer

B. Monk, A. Oza, I. Vergote, 2023, Clinical cancer research : an official journal of the American Association for Cancer Research.

Tisotumab Vedotin in Combination With Carboplatin, Pembrolizumab, or Bevacizumab in Recurrent or Metastatic Cervical Cancer: Results From the innovaTV 205/GOG-3024/ENGOT-cx8 Study

B. Monk, I. Vergote, M. Zikan, 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.